Evotec SE has announced its financial results for the first half of 2025, highlighting significant progress in strategy implementation for sustainable and profitable growth. The company reported a consolidated revenue of €371.2 million, representing a 5% decrease. The Discovery & Preclinical Development (D&PD) segment experienced an 11% decline in demand, while Just - Evotec Biologics (JEB) exceeded expectations with a 16% increase in revenues to €102.2 million, driven by an expanded customer base. The adjusted consolidated EBITDA stood at -€1.9 million, aligning with expectations due to effective cost control measures across the organization. The company has made decisive advancements in its collaborations, notably with Bristol Myers Squibb in targeted protein degradation and neurology, and announced a significant development in its strategic partnership with Sandoz on July 30. For future outlook, Evotec SE anticipates an adjusted consolidated EBITDA of between €30 to €50 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.